Durvalumab vs placebo consolidation therapy after chemoradiotherapy in stage III non-small-cell lung cancer: An updated PACIFIC trial-based cost-effectiveness analysis - Lung Cancer
PACIFIC: Durvalumab in Stage III NSCLC - Capsule Summary Slidesets - 2018 WCLC Annual Meeting - Oncology - Clinical Care Options
Gerry Hanna 💙 on Twitter: "PACIFIC study - adjuvant Durvalumab demonstrates a major step change in the management of stage 3 NSCLC with a clear increase in OS #WCLC2018 @IASLC @BTOGORG #radonc @
PACIFIC 5-Yr Update - Capsule Summary Slidesets - Lung Cancer - 2021 ASCO Virtual Annual Meeting - Oncology - Clinical Care Options
Patient-reported outcomes with durvalumab after chemoradiotherapy in stage III, unresectable non-small-cell lung cancer (PACIFIC): a randomised, controlled, phase 3 study - The Lancet Oncology
Four-Year Survival With Durvalumab After Chemoradiotherapy in Stage III NSCLC—an Update From the PACIFIC Trial - ScienceDirect
Three-Year Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC—Update from PACIFIC - Journal of Thoracic Oncology
First-line Durvalumab Improves Survival
Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer | NEJM
IMFINZI® (durvalumab) Efficacy for Unresectable Stage III NSCLC
A Phase III Study of Durvalumab (MEDI4736) With or Without Tremelimumab for Previously Treated Patients With Advanced NSCLC: Rationale and Protocol Design of the ARCTIC Study - Clinical Lung Cancer
Stage III NSCLC - NSCLC Treatment Paradigm - Text Module - NSCLC Practical Guidance - Oncology - Clinical Care Options
Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC | NEJM
Neoadjuvant durvalumab with or without stereotactic body radiotherapy in patients with early-stage non-small-cell lung cancer: a single-centre, randomised phase 2 trial - The Lancet Oncology
Real world data of durvalumab consolidation after chemoradiotherapy in stage III non-small-cell lung cancer - Lung Cancer
PACIFIC: 5-Year Survival Outcomes With Consolidation Durvalumab vs Placebo After Concurrent CRT in Unresectable Stage III NSCLC
AstraZeneca presents superior progression-free survival for IMFINZI® ( durvalumab) in the PACIFIC trial of patients with locally-advanced unresectable lung cancer at ESMO 2017 Congress
Durvalumab in non-small-cell lung cancer patients: current developments. | Semantic Scholar
Outcomes with durvalumab by tumour PD-L1 expression in unresectable, stage III non-small-cell lung cancer in the PACIFIC trial - ScienceDirect
david vicente baz on Twitter: "Very proud of our contribution to PACIFIC clinical trial. Durvalumab as new standard of care in unresectable stage III non small cell lung cancer after chemoradiotherapy Many
Beyond chemoradiotherapy: improving treatment outcomes for patients with stage III unresectable non-small-cell lung cancer through immuno-oncology and durvalumab (Imfinzi®▽, AstraZeneca UK Limited) | British Journal of Cancer
Cancers | Free Full-Text | Real World Outcomes versus Clinical Trial Results of Durvalumab Maintenance in Veterans with Stage III Non-Small Cell Lung Cancer | HTML
Durvalumab - Wikipedia
First-line Durvalumab Improves Survival
Durvalumab Improves 5-year OS and PFS in Patients With Unresectable Stage III NSCLC
Durvalumab in non-small-cell lung cancer patients: current developments. | Semantic Scholar
PACIFIC survival explained: Cancer spread red | EurekAlert!
Exploratory 3-year overall survival for patients with unresectable... | Download Scientific Diagram
